Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

Antonio Russo; Francesco Pantano; Elisa Giommoni; Salvatore Pisconti; Fernando De Vita; Anna Elisabetta Brunetti; Paola Bertocchi; Antonio Trogu; Alessandro Comandone; Vincenzo Catalano; Silvana Leo; Francesco Angelini; Francesco Angelini; Raimondo Ferrara; Maria Antonietta Satolli; Amalia Azzariti; Antonio Febbraro; Saverio Cinieri; Teresa Gamucci; Evaristo Maiello; Teresa Di Palma; Ferdinando Riccardi; Nicola Silvestris; Paolo Pedrazzoli; Raimondo Ferrara; Toni Ibrahim; Antonio Bernardo; Alessandro Bertolini; Rossana Berardi; Sandro Barni; Daniele Santini

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

Antonio Russo, Francesco Pantano, Elisa Giommoni, Salvatore Pisconti, Fernando De Vita, Anna Elisabetta Brunetti, Paola Bertocchi, Antonio Trogu, Alessandro Comandone, Vincenzo Catalano, Silvana Leo, Francesco Angelini, Francesco Angelini, Raimondo Ferrara, Maria Antonietta Satolli, Amalia Azzariti, Antonio Febbraro, Saverio Cinieri, Teresa Gamucci, Evaristo MaielloTeresa Di Palma, Ferdinando Riccardi, Nicola Silvestris, Paolo Pedrazzoli, Raimondo Ferrara, Toni Ibrahim, Antonio Bernardo, Alessandro Bertolini, Rossana Berardi, Sandro Barni, Daniele Santini

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Article

31 Citazioni (Scopus)

Abstract

Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. Themedian time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bonemetastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlatedwith a shorter time to diagnosis of bone metastases (p = 0.001, HR = 1.819). The median survival from bone metastasis was 7months. At multivariate analysis, HCC etiology (p = 0.005), ECOG performance status (p = 0.002) and treatment withbisphosphonate (p = 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasisbut not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p = 0.021) and OS(p = 0.001).Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease inHCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequentworsening of their quality of life.

Lingua originale	English
Numero di pagine	8
Rivista	PLoS One
Volume	9
Stato di pubblicazione	Published - 2013

Fingerprint

All Science Journal Classification (ASJC) codes

Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
General

Cita questo

Russo, A., Pantano, F., Giommoni, E., Pisconti, S., De Vita, F., Brunetti, A. E., Bertocchi, P., Trogu, A., Comandone, A., Catalano, V., Leo, S., Angelini, F., Angelini, F., Ferrara, R., Satolli, M. A., Azzariti, A., Febbraro, A., Cinieri, S., Gamucci, T., ... Santini, D. (2013). Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. PLoS One, 9.

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. / Russo, Antonio; Pantano, Francesco; Giommoni, Elisa; Pisconti, Salvatore; De Vita, Fernando; Brunetti, Anna Elisabetta; Bertocchi, Paola; Trogu, Antonio; Comandone, Alessandro; Catalano, Vincenzo; Leo, Silvana; Angelini, Francesco; Angelini, Francesco; Ferrara, Raimondo; Satolli, Maria Antonietta; Azzariti, Amalia; Febbraro, Antonio; Cinieri, Saverio; Gamucci, Teresa; Maiello, Evaristo; Di Palma, Teresa; Riccardi, Ferdinando; Silvestris, Nicola; Pedrazzoli, Paolo; Ferrara, Raimondo; Ibrahim, Toni; Bernardo, Antonio; Bertolini, Alessandro; Berardi, Rossana; Barni, Sandro; Santini, Daniele.

In: PLoS One, Vol. 9, 2013.

Risultato della ricerca: Article

Russo, A, Pantano, F, Giommoni, E, Pisconti, S, De Vita, F, Brunetti, AE, Bertocchi, P, Trogu, A, Comandone, A, Catalano, V, Leo, S, Angelini, F, Angelini, F, Ferrara, R, Satolli, MA, Azzariti, A, Febbraro, A, Cinieri, S, Gamucci, T, Maiello, E, Di Palma, T, Riccardi, F, Silvestris, N, Pedrazzoli, P, Ferrara, R, Ibrahim, T, Bernardo, A, Bertolini, A, Berardi, R, Barni, S & Santini, D 2013, 'Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey', PLoS One, vol. 9.

Russo, Antonio ; Pantano, Francesco ; Giommoni, Elisa ; Pisconti, Salvatore ; De Vita, Fernando ; Brunetti, Anna Elisabetta ; Bertocchi, Paola ; Trogu, Antonio ; Comandone, Alessandro ; Catalano, Vincenzo ; Leo, Silvana ; Angelini, Francesco ; Angelini, Francesco ; Ferrara, Raimondo ; Satolli, Maria Antonietta ; Azzariti, Amalia ; Febbraro, Antonio ; Cinieri, Saverio ; Gamucci, Teresa ; Maiello, Evaristo ; Di Palma, Teresa ; Riccardi, Ferdinando ; Silvestris, Nicola ; Pedrazzoli, Paolo ; Ferrara, Raimondo ; Ibrahim, Toni ; Bernardo, Antonio ; Bertolini, Alessandro ; Berardi, Rossana ; Barni, Sandro ; Santini, Daniele. / Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. In: PLoS One. 2013 ; Vol. 9.

@article{b6c33532c9f04b90a1d97546bfe61e97,

title = "Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey",

abstract = "Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. Themedian time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bonemetastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlatedwith a shorter time to diagnosis of bone metastases (p = 0.001, HR = 1.819). The median survival from bone metastasis was 7months. At multivariate analysis, HCC etiology (p = 0.005), ECOG performance status (p = 0.002) and treatment withbisphosphonate (p = 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasisbut not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p = 0.021) and OS(p = 0.001).Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease inHCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequentworsening of their quality of life.",

author = "Antonio Russo and Francesco Pantano and Elisa Giommoni and Salvatore Pisconti and {De Vita}, Fernando and Brunetti, {Anna Elisabetta} and Paola Bertocchi and Antonio Trogu and Alessandro Comandone and Vincenzo Catalano and Silvana Leo and Francesco Angelini and Francesco Angelini and Raimondo Ferrara and Satolli, {Maria Antonietta} and Amalia Azzariti and Antonio Febbraro and Saverio Cinieri and Teresa Gamucci and Evaristo Maiello and {Di Palma}, Teresa and Ferdinando Riccardi and Nicola Silvestris and Paolo Pedrazzoli and Raimondo Ferrara and Toni Ibrahim and Antonio Bernardo and Alessandro Bertolini and Rossana Berardi and Sandro Barni and Daniele Santini",

year = "2013",

language = "English",

volume = "9",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

}

TY - JOUR

T1 - Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

AU - Russo, Antonio

AU - Pantano, Francesco

AU - Giommoni, Elisa

AU - Pisconti, Salvatore

AU - De Vita, Fernando

AU - Brunetti, Anna Elisabetta

AU - Bertocchi, Paola

AU - Trogu, Antonio

AU - Comandone, Alessandro

AU - Catalano, Vincenzo

AU - Leo, Silvana

AU - Angelini, Francesco

AU - Ferrara, Raimondo

AU - Satolli, Maria Antonietta

AU - Azzariti, Amalia

AU - Febbraro, Antonio

AU - Cinieri, Saverio

AU - Gamucci, Teresa

AU - Maiello, Evaristo

AU - Di Palma, Teresa

AU - Riccardi, Ferdinando

AU - Silvestris, Nicola

AU - Pedrazzoli, Paolo

AU - Ferrara, Raimondo

AU - Ibrahim, Toni

AU - Bernardo, Antonio

AU - Bertolini, Alessandro

AU - Berardi, Rossana

AU - Barni, Sandro

AU - Santini, Daniele

PY - 2013

Y1 - 2013

N2 - Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. Themedian time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bonemetastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlatedwith a shorter time to diagnosis of bone metastases (p = 0.001, HR = 1.819). The median survival from bone metastasis was 7months. At multivariate analysis, HCC etiology (p = 0.005), ECOG performance status (p = 0.002) and treatment withbisphosphonate (p = 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasisbut not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p = 0.021) and OS(p = 0.001).Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease inHCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequentworsening of their quality of life.

AB - Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. Themedian time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bonemetastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlatedwith a shorter time to diagnosis of bone metastases (p = 0.001, HR = 1.819). The median survival from bone metastasis was 7months. At multivariate analysis, HCC etiology (p = 0.005), ECOG performance status (p = 0.002) and treatment withbisphosphonate (p = 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasisbut not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p = 0.021) and OS(p = 0.001).Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease inHCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequentworsening of their quality of life.

UR - http://hdl.handle.net/10447/99194

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

ER -

Accesso al documento

OA Link